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Abstract
Glioblastoma multiforme (GBM), designated as World Health Organization (WHO) grade IV astrocytoma, is a
lethal and therapy-resistant brain cancer comprised of several tumor cell subpopulations, including GBM stem cells
(GSCs) which are believed to contribute to tumor recurrence following initial response to therapies. Emerging evi-
dence demonstrates that GBM tumors are initiated from GSCs. The development and use of novel therapies includ-
ing small molecule inhibitors of specific proteins in signaling pathways that regulate stemness, proliferation and
migration of GSCs, immunotherapy, and non-coding microRNAs may provide better means of treating GBM.
Identification and characterization of GSC-specific signaling pathways would be necessary to identify specific ther-
apeutic targets which may lead to the development of more efficient therapies selectively targeting GSCs. Several
signaling pathways including mTOR, AKT, maternal embryonic leucine zipper kinase (MELK), NOTCH1 and
Wnt/b-catenin as well as expression of cancer stem cell markers CD133, CD44, Oct4, Sox2, Nanog, and
ALDH1A1 maintain GSC properties. Moreover, the data published in the Cancer Genome Atlas (TCGA) specifi-
cally demonstrated the activated PI3K/AKT/mTOR pathway in GBM tumorigenesis. Studying such pathways may
help to understand GSC biology and lead to the development of potential therapeutic interventions to render them
more sensitive to chemotherapy and radiation therapy. Furthemore, recent demonstration of dedifferentiation
of GBM cell lines into CSC-like cells prove that any successful therapeutic agent or combination of drugs
for GBM therapy must eliminate not only GSCs, but the differentiated GBM cells and the entire bulk of tumor
cells.
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Introduction
Glioblastoma multiforme (GBM) is the largest group
of brain tumors with very poor response to current thera-
pies
[1]
. Approximately 13,000 people die annually from
GBM in the United States, and unfortunately only
about 10% of patients survive 5 years
[2-4]
. Despite very
significant efforts taken to advance therapeutic strate-
gies for patients with GBM, the clinical prognosis for
this devastating disease remains grim. While the combi-
nation of radiotherapy and adjunct temozolomide
(TMZ) has increased the survival of patients with
GBM, the median survival of GBM patients is only
about 14.6 months
[5]
. GBM tumors display inter- and
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intra-patient genomic and phenotypic diversity which
originates from the complicated dynamics that form a
solid foundation for their development and progression.
This genotypic and phenotypic diversity causes varia-
tion in tumor response to therapy between patients with
the same tumor type. Several factors including the
tumor environment, pharmacodynamics, as well as
intertumor and intratumoral heterogeneity in individual
patients contribute to this variability
[6-9]
. Various genetic
alterations which result in redundant and increased
cytoprotective and survival pathways as well as numer-
ous defects in the apoptotic signaling machinery
and epigenetic alterations contribute to the highly
aggressive nature of GBM (Fig. 1). The main cause
of death in patients with GBM is recurrence of themalig-
nancy which is attributed to treatment-resistant GBM
stem cells (GSCs) within the primary tumor and sur-
rounding the tumor.
Substantial evidence indicates that cancer stem cells
(CSCs) or cancer-initiating cells (CICs), play a signifi-
cant role in several cancers, includingGBM
[10-12]
. It iswell
documented that GBM displays a high degree of pheno-
typic, cellular, genetic, and epigenetic heterogeneity.
Furthermore, recent evidence clearly indicates that a
major problem in the unresponsiveness of GBM tumors
to therapy is the existence of GSCs within the tumor
which aremost crucial for driving invasive tumor growth
and relapse
[10,13]
. Interestingly, in GBM and other malig-
nancies, CSC enrichment may occur either from an
increased symmetric self-renewal division rate of
CSCs or a reprogramming of non-CSC to CSCs
which results in phenotypic plasticity in the tumor
population
[14-15]
. The concept of dedifferentiation of
non-CSCs to CSCs has increased the complexity of
understanding tumor heterogeneity, a potential
mechanism for therapeutic relapse, resistance to antic-
ancer therapies, and concerns regarding developing
therapeutic strategies.
GBMs harbor dynamic subpopulations of GSCs that
have specific phenotypic and genotypic characteristics
and can propagate in vivo
[15]
. Since emerging evidence
strongly indicates that CSCs are responsible for resis-
tance to therapies in cancer patients, discovering distinct
targets and delineating the molecular differences that
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Fig. 1 Diagram of proliferation, apoptosis- and therapy-resistance, invasion, and the key pathways in glioblastoma multiforme
(GBM) and GBM stem cells (GSCs). In this model, the very invasive GBM cells have a slower rate of proliferation, but the highly proliferative
cells display a less invasive phenotype. GBM progression and development are determined by three main factors: GBM cell proliferation rate, tumor cell
migration, and their resistance to apoptosis and anticancer therapy. Several major proteins including Myc, EGF, VEGF, and bFGF (basic fibroblast
growth factor) play major roles in GBM cell proliferation state. Microenvironmental factors (niche) including angiogenesis, tumor extracellular matrix
(ECM), and anaerobic glycolysis promote repopulation of tumors and play important roles in regulating the rate of GSC production. Furthermore,
chemotherapy, ionizing radiation, and hypoxia can trigger epigenetic plasticity and force induction of GSCs which express proteins involved in
apoptosis and therapy resistance including MGMT, P-glycoprotein, DNA-PK, mTOR, CD133, and Oct-3/4. Modified from Xie et al.
[96]
.
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drive CSC phenotypes hold enormous significance and
promise for improving cancer therapy. Particularly,
developing targeted inhibitors with the ability to selec-
tively suppress such targets and the molecular drivers
of stemness in CSCs may profoundly affect future can-
cer treatment. In this review article, several signaling
pathways that regulate the survival and proliferation of
GSCs and the potential of specific proteins in these path-
ways for developing novel and effective inhibitors to
eliminate these cells are discussed. Moreover, further
understanding GBM cell plasticity and its underlying
molecular mechanisms will help in the design of more
effective therapies against GBM and preventing tumor
recurrence.
GBM
Primary GBM is the most common form of brain
tumors
[1-2]
and is designated as World Health Organi-
zation (WHO) grade IV astrocytoma
[16-19]
. Primary
GBM is very aggressive and its initiation and recurrence
is believed to be caused by GSCs which may be derived
from mutated neural stem and precursor cells
[13-19]
.
Furthermore, in contrast to the origin of primary
GBM, secondary GBM tumors are developed from
lower-grade astrocytomas or oligodendrogliomas.
While both types are histologically similar, they are
genetically different
[15-16]
. Primary GBM frequently
expresses molecular alterations in EGFR, PDGFRA,
PTEN, p53, NF1, CDKN2A/B, and telomerase reverse
transcriptase (TERT) promoter mutations
[21-2 2 ]
.
Furthermore, global hypomethylation is frequently
observed in primary human GBM
[23]
. The most detailed
information on GBM has been provided by the Cancer
Genome Atlas (TCGA) Research Network reporting
analysis of copy number, methylation patterns, expres-
sion profiling, and whole-genome sequencing of GBM
samples
[24]
. A number of genes including EGFR,
PDGFRA, CDK4, MDM2, MDM4, MET, CDK6, N-
Myc, Cyclin D2, PIK3CA, and AKT3 have been found
amplified in GBM
[20]
. Additionally, significant abnorm-
alities in several signaling pathways including the recep-
tor tyrosine kinase pathway, the p53 pathway, and the
RB pathway were found
[17,20,24]
. Therefore, these data
emphasize the complexity in developing therapies to
treat GBM.
One molecular marker that is expressed in a subset of
GBM cells is the truncated epidermal growth factor recep-
tor (EGFR) mutant referred to as EGFRvIII
[25,26]
. This
EGFR variant functions as a ligand-independent constitu-
tively active receptor and displays robust tumorigenic
activity and promotes cellular proliferation via activation
of the MAPK and phosphatidylinositol-3-kinase (PI3K)
Akt pathways
[26]
. This mutation usually occurs in associa-
tion with the amplification and overexpression of wild-
type EGFR (wtEGFR). However, despite EGFRvIII’s
potent ability to enhance tumorigenicity, its expression
is usually seen only in a subpopulation of cells
[27]
.
EGFRvIII is an interesting target in GBM therapy
because of new EGFRvIII vaccine trials underway
[26,28]
.
Padfield et al.
[26]
have reviewed the signaling pathways
of EGFR and EGFRvIII and the targeted therapy
approaches including tyrosine kinase inhibitor, anti-
body-based therapies, vaccines and pre-clinical RNA-
based therapies, as well as the complexities encountered
with these molecular targeting approaches including
pathway redundancy and intratumoral heterogeneity.
Cancer therapy and drug resistance in
CSCs and tumors
In 1979, Goldie and Coldman
[29]
proposed the first sim-
ple and elegant mathematical model of drug sensitivity of
tumors to their mutation rates. The model indicates that
the probability of the appearance of a resistant phenotype
increases with the mutation rate. Moreover, for tumors
with a nonzero mutation rate the likelihood of there being
at least one resistant cell will go from a condition of low to
high probability in a very short time. Goldie and
Coldman
[30]
with a simulation approach further expanded
their model and explained why an alternating non-cross-
resistant chemotherapy is optimal. This model stated that
the acquisition of multiple levels of drug resistance hap-
pens at an accelerated pace and leads to increased degrees
of incurability for tumors with a stem cell compartment of
a given size. Therefore, based on this model the heteroge-
neity of slow-growing advanced higher stage clinical
tumors will be very high. Furthermore, Foo and
Michor
[31]
reported that drug resistance can emerge
due to a host of environmental factors as well as
genetic or epigenetic alterations in cancer cells. These
factors are particularly important in the interconversion
of CSCs to differentiated cells and vice versa
[15]
which
make the therapeutic approaches quite complicated.
Notably, evolutionary theory has contributed to our
understanding of the dynamics of resistance mutations
in a cancer cell population, the risk of resistance pre-
existing before the initiation of therapy, the drug cock-
tail composition necessary to prevent the emergence of
resistance, and optimum drug administration schedules
for patients at risk of evolving acquired resistance
[31]
.
Furthermore, much evidence demonstrates that CSCs
contribute to tumor resistance to therapy and recurrence
of tumors
[15]
. Adding to the complexity of successful
treatment of tumors is the recent demonstration of ded-
ifferentiation of differentiated cancer cells into CSC-like
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cells due to epigenetic plasticity
[15]
, which proves that
any successful therapeutic agent or combination of
drugs for cancer therapy must eliminate not only
GSCs, but differentiated cancer cells, and the entire
bulk of tumor cells.
GSCs signaling pathways
GBM is initiated from the transformation of
neural stem cells (NSCs) into GSCs. Similarly, glial
progenitors are able to trigger tumor development follow-
ing malignant transformation of normal progenitor
cells
[32]
. Astrocytes, neurons, oligodendrocytes, and epen-
dymal cells also have the potential to initiate tumorigen-
esis
[32]
. Stem cell-like properties of GSCs could also be
acquired during transformation and differentiated non-
stem cancer cells can undergo dedifferentiation to form
tumor stem-like cells. Recently, Friedmann-Morvinski
et al.
[33]
investigated the mechanisms of dedifferentia-
tion/reprogramming achieved by cortical mature neurons
and astrocytes upon transduction with a lentiviral vector
containing HRasV12 and shp53.4. These authors con-
firmed that while transformed dedifferentiated astrocytes
and neurons acquired a stem/progenitor cell state, they
still retained gene expression memory from their parental
cell. Moreover, transcriptional network analysis identi-
fied upregulated genes in three main pathways in these
cells: Wnt signaling, cell cycle and focal adhesion with
the gene Spp1 [also knownas osteopontin (OPN)] serving
as a common node connecting these pathways. The for-
mation of neurospheres was OPN-dependent, and OPN
inhibition in both murine and human glioma tumors
prolonged mice survival. These significant results
demonstrated that OPN plays an important role in dedif-
ferentiation of cells during tumor formation. Therefore,
inhibition of OPN can be a therapeutic target for eliminat-
ing GSCs and GBM therapy.
Emerging evidence has demonstrated that GBM ori-
ginates from CSCs and that GSCs are responsible for
cancer patient resistance to therapies
[34-36]
. Therefore,
identifying the molecular differences that drive GSC
phenotypes and discovering distinct targets will provide
significant promise for developing targeted inhibitors
for cancer therapy. Fig. 2 summarizes the characteris-
tics of GSCs which include specific cell surface markers
and particular networks of transcription factor (TF) sig-
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Fig. 2 Characteristics and potential targets of GSCs. Various factors and cellular processes control GSC phenotype including specific cell
surface markers and particular networks of transcription factors (TF) signaling, aberrant signaling pathways, epigenetic alterations, reprograming and
plasticity, interaction with the microenvironment and GSCs niche, and particular metabolic pathways.
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naling, aberrant signaling pathways, epigenetics altera-
tions, reprograming and plasticity, interaction with the
microenvironment andGSCs niche, and using particular
metabolic pathways. In this review article, several sig-
naling pathways that regulate the survival and prolifera-
tion of GSCs and the potential of targeting specific
proteins in these pathways to identify and develop novel
and effective inhibitors for eliminating these cells are
discussed. Characterizing and delineating CSC-specific
signaling pathways would help to identify novel
therapeutic targets and may lead to the development of
more robust and efficient therapies selectively targeting
GSCs. Recent work has revealed how normal stem cells
(SCs) switch between functional states adjusting to
homoeostasis or regeneration
[37]
. This plasticity is also
seen in differentiating cells which are capable of revert-
ing to SCs after injury. Similar plasticity in cancer cells
has also been reported
[15]
. Interestingly, Olmez et al.
[35]
recently induced dedifferentiation of patient-derived
GBM cell lines into GSC-like cells (induced GBM stem
cells, iGSCs) through the expression of Oct4, Sox2 and
Nanog transcription factors. Compared with parental
GBM cells, iGSCs cells showed significant suppression
of EGF receptor and its downstream pathways, formed
large neurospheres even in the absence of exogenous
mitogens, displayed significant sensitivity to the CSC
inhibitor salinomycin, and exhibited resistance to
TMZ therapy. Moreover, NOTCH1 and Wnt/b-catenin
signaling and expression of CD133, CD44 and
ALDH1A1 were induced in iGSCs. These results indi-
cate that dedifferentiation of GBM cells to iGSCs causes
complexity in treating this disease and that any therapeu-
tic intervention should be designed to eliminate GSCs as
well as iGSCs which may result from treatment with the
chemotherapeutic agent TMZ or radiation therapy
[15]
.
Studies conducted by the Cancer Genome Atlas
(TCGA) also demonstrate the roles of several molecular
pathways, specifically the activated PI3K/AKT/mTOR
signaling pathway in GSCs and GBM tumorigenesis
[20]
.
Inhibition of multiple molecular pathways may provide
an innovative therapeutic approach for managing GBM.
Another important protein, the serine/threonine kinase
maternal embryonic leucine-zipper kinase (MELK),
plays a major role in GSCs. MELK binds and phosphor-
ylates the oncogenic transcription factor FOXM1 in
GSCs and recent results show that the catalytic subunit
of Polycomb repressive complex 2, EZH2, is targeted by
the MELK-FOXM1 complex, which in turn promotes
GSC resistance to radiation
[38]
. Clinically, EZH2 and
MELK are co-expressed in GBM and significantly
induced in post-irradiation recurrent tumors whose
expression is inversely correlated with patient prog-
nosis
[38]
. Through a gain-and loss-of-function study,
these authors show that MELK or FOXM1 contributes
to GSC radioresistance by regulating EZH2.
Therefore, MELK-FOXM1-EZH2 signaling axis is
essential for GSC radioresistance and therefore raises
the possibility that MELK-FOXM1-driven EZH2 sig-
naling can serve as a therapeutic target in irradiation-
resistant GBM tumors.
We were the first to demonstrate the indispensible role
of DNA-dependent protein kinase (DNA-PK) in elevating
the expression of P-gp and an siRNA or a small molecule
inhibitor ofDNA-PKabrogating P-gp expression and drug
resistance
[39]
. A recent report emphasized the importance of
the MDR1 gene and its product P-glycoprotein (P-gp) in
GSCs resistance to chemotherapy by showing that follow-
ing prolonged chemotherapy,DNA-PK, P-gp andCD133
+
increase in recurrent GBM
[40]
. Interestingly, doxorubicin
markedly increased CD133, DNA-PK and MDR1 in
GBM cells
[40]
. Their results show that CD133 and DNA-
PKmay increaseMDR1 via the PI3K-Akt signal pathway.
The PI3K downstream targets Akt and nuclear factor NF-
kB, which interacts with the MDR1 promoter, were also
increased in these cells. Downregulation of CD133 and
DNA-PK by small interfering RNA, or inhibition of
PI3K or Akt, decreased Akt, NF-kB and MDR1 expres-
sion. Therefore, targeting CD133 and DNA-PK in combi-
nation with conventional chemotherapy may effectively
eliminate GBMcells andGSCs and improve the prognosis
for patients with GBM.
Adherent cultures of GSCs grown on laminin-coated
plates (Ad-GSCs) and spheroid cultures of GSCs (Sp-
GSCs) expressed high levels of stem cell markers,
CD133, Sox2 and Nestin, but low expression of differ-
entiation markers (bIII-tubulin and glial fibrillary acid
protein)
[41]
. Recently, Garner et al.
[41]
have characterized
GBM tumors generated by subcutaneous and intracra-
nial injection of Ad-GSCs and Sp-GSCs isolated from
a patient-derived xenoline. Interestingly, while these
GSCs formed tumors with identical histological fea-
tures, gene expression analysis showed that xenografts
of Sp-GSCs had a classical molecular subtype similar
to the bulk tumor cells. In contrast, xenografts generated
from Ad-GSCs expressed a mesenchymal gene signa-
ture. Furthermore, Ad-GSC-derived xenografts had
high STAT3 and ANGPTL4 expression, enriched stem
cell markers, transcriptional networks and proangio-
genic markers. In clinical samples from GBM patients,
STAT3 expression was directly correlated with
ANGPTL4 expression. Moreover, increased expression
of these genes correlated with poor patient survival.
These authors further demonstrated that a pharmacologi-
cal STAT3 inhibitor suppressed STAT3 binding to the
ANGPTL4 promoter and exerted anticancer activity
in vivo. Therefore, two distinct sub-populations of
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GSCs, Ad-GSCs and Sp-GSCs, generated histologically
identical tumors with different gene expression patterns,
and a STAT3/ANGPTL4 pathway is only identified in
Ad-GSC-derived xenografts. Consequently, several tar-
gets distinct to each GSC sub-population should be used
for more robust GBM therapeutic intervention.
Mao et al.
[42]
using patient tumor-derived GSCs
recently demonstrated that the mitotic E3 ubiquitin
ligase CDC20-anaphase-promoting complex (CDC20-
APC) drives invasiveness and self-renewal. These
authors showed that CDC20 knockdown inhibited
and CDC20 overexpression increased the capacity of
human GSCs to generate brain tumors in an orthotopic
xenograft model in vivo. Moreover, CDC20-APC trig-
gered GSC invasion and self-renewal occurred through
pluripotency-related transcription factor SOX2.
Therefore, the CDC20-APC/SOX2 signaling axis is
indispensible for control of key biological properties
of GSCs, and may serve as targeted strategies for the
development of novel and effective GBM therapy.
Targeting of CSCs
GBM recurrence occurs largely from remaining CSCs
after initial therapy and from epigenetic plasticity and
interconversion of the differentiated GBM cells to
GSCs resulting from the initial treatment
[15,43,44]
.
Therefore, since the heterogeneity of GSCs increase the
complexity of targeting CSCs, any effective and success-
ful GBM therapy must consider eliminating both GSCs
as well as the entire bulk of the tumor. Emerging evi-
dence has revealed that the GSC behavior is more
dynamic than originally envisioned. Interaction of
GSCs with its niche with respect to its exposure to
hypoxia and intercellular communication in proximity
to endothelial or bone marrow-derived cells (BMDC)
may activate GSCs signaling pathways. GBM are excep-
tionally stroma-rich tumors and may consist of more than
70% stromal components, such as microglia and BMDC.
It becomes increasingly apparent that multi-targeted stra-
tegies are needed to treat GBM, and recent approaches in
GBM therapy include inhibition of invasion (e.g., integ-
rin, EGFR, CD95, and mTOR inhibition), antiangiogen-
esis and stroma modulators (TGFbeta, VEGF,
angiopoetin, and cMET inhibitors), and activation of
the immune response (vaccination and blockage of nega-
tive co-stimulatory signals)
[45]
.
To eliminate GSCs, one strategy is to use an anti-CSC
drug and a drug that epigenetically targets GSCs as well
as GBM cells. For example, Booth et al.
[46]
demonstrated
that the lethality of low nanomolar concentrations of sali-
nomycin, a CSC inhibitor, is enhanced by clinically used
HDAC inhibitors valproate and vorinostat in GBM cells.
These authors demonstrated that regardless of PTEN,
ERBB1, or p53 mutational status, salinomycin interacted
with HDAC inhibitors in a synergistic fashion to kill
GBM cells. The HDAC inhibitor, suberanilohydroxamic
acid (SAHA) was recently demonstrated to trigger autop-
hagy through the downregulation of AKT-mTOR signal-
ing, a major suppressive cascade of autophagy
[47]
.
Interestingly, upon pharmacological inhibition of autop-
hagy, SAHA facilitates apoptosis and results in cell death
at the early phase, suggesting that SAHA-induced autop-
hagy functions probably act as a prosurvival mechanism.
Furthermore, their results also indicated that the inhibition
of SAHA-induced autophagy using chloroquine has syner-
gistic effects that further increase apoptosis. These results
provide a new perspective on the treatment of GSCs, indi-
cating that SAHA targets GSCs through the induction of
autophagy.
Another proposed strategy for targeting GSCs is to
first induce differentiation, thus making these cells more
amenable to other therapeutic agents. A recent study by
Friedman et al.
[48]
examined this approach by using
mTOR inhibition alone and in combination with the dif-
ferentiating agent all-trans retinoic acid (ATRA) that
can target CSCs. The results demonstrated that ATRA,
a derivative of retinol, caused differentiation of GSCs
as evidenced by the loss of stem cell marker nestin
expression. Aberrant function of mTORhas been shown
in GSCs. Expression of activated extracellular signal-
regulated kinase 1/2 (pERK1/2) was also increased by
ATRA treatment, independent of mTOR pathway inhi-
bitors. The motility of GBM cells was decreased by
treatment with ATRA, rapamycin and the PI3K inhibi-
tor LY29002 alone. Interestingly, combination treat-
ment synergistically inhibited effects on GBM cells
migration. These findings indicate that ATRA-induced
differentiation is mediated via the ERK1/2 pathway
and underscores the significance of including differen-
tiating agents along with inhibitors of mTOR pathways
in the treatment of GBM.
Combinational inhibition of phosphoinositide-3-
kinase/Akt/mammalian target of rapamycin (mTOR)
and mitogen-activated protein/extracellular signal-regu-
lated kinase kinase (MEK)/extracellular signal-regulated
kinase (ERK) pathways effectively promotes the commit-
ment of glioblastoma cancer stem-like cells (CSLCs) to
differentiation and thereby suppresses their tumorigeni-
city
[49]
. However, the mechanism by which these two sig-
na l ing pathways are coordina ted to regula te
differentiation and tumorigenicity remains unknown.
FoxO3a, a common phosphorylation target for Akt and
ERK, is a major transcription factor which was identified
to integrate the signals from these pathways
[49]
. Inhibition
of Akt and ERK pathways caused nuclear accumulation
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and activation of FoxO3a more effectively than blockade
of either alone, and promoted differentiation of GSCs in a
FoxO3a expression-dependent fashion. Furthermore, the
expression of a constitutively active FoxO3amutant lack-
ing phosphorylation sites for both Akt and ERK was
enough to induce differentiation and reduce the tumori-
genicity ofGSCs. Hence, FoxO3amay play a pivotal role
in controlling the differentiation and tumorigenicity of
GSCs by the PI3K/Akt/mTOR and MEK/ERK signaling
pathways. These data also suggest that developing strate-
gies targeting FoxO3a activation could be potentially use-
ful for the treating GBM.
Di Cristofori
[50]
recently reported that the vacuolar H+
ATPase (V-ATPase) ATP6V1G1 was unregulated in a
series of GBM and GSC neurospheres isolated from
GBM patients, and this protein correlated with shorter
overall survival. ATP6V1G1 knockdown in GBM neuro-
spheres curtailed sphere-forming ability, induced cell
death, and decreasedmatrix invasion. Treating GSCs neu-
rospheres with bafilomycin A1, the selective V-ATPase
inhibitor, reproduced the effects of ATP6V1G1 siRNA
and strongly inhibited the expression of the stem cell mar-
kers nestin and CD133, and transcription factors SALL2
and POU3F2 in neurospheres. Therefore, ATP6V1G1
serves as a novel marker of poor prognosis in GBM
patients and its inhibitors can serve as a new therapeu-
tic strategy for GBM.
Aderegulated apoptotic pathwaywith high levels of the
antiapoptotic Bcl-2 family of proteins and overt activity of
the PI3K signaling pathway has been detected in GBM
and GSCs
[51]
. Moreover, ABT-263 (Navitoclax), an orally
available small-molecule BH-3 mimetic Bcl-2 inhibitor,
and GDC-0941, a PI3K inhibitor, abrogated the ability
of GSCs to form neurospheres
[51]
. Furthermore, the anti-
apoptotic Bcl-2 family protein Mcl-1 is overexpressed
in GBM and represents an important resistance factor to
the BH-3 mimetic ABT263. GX15-070, a pan-Bcl-2 inhi-
bitor which has shown promising antitumor activity in dif-
ferent malignancies, and combined treatment with
ABT263 and GX15-070 overcomes apoptotic resistance
in established GBM cell lines, glioma stem-like cells,
primary cultures, and in in vivo experiments
[52]
. At the
molecular level, GX15-070 enhanced apoptosis by post-
translational down-regulation of the deubiquitinase,
Usp9X, and the chaperone Bag3, leading to a sustained
depletion of Mcl-1 protein levels. Furthermore, knock-
down of Usp9X or Bag3 depleted endogenousMcl-1 pro-
tein levels and in turn enhanced apoptosis induced
through Bcl-2/Bcl-xL inhibition
[52]
. Therefore, inhibiting
Mcl-1 expression may be a good therapeutic approach
and a novel target in GBM therapy.
MicroRNAs and other epigenetic factors
in GSCs
Recent results have revealed that microRNAs
(miRNAs) play important regulatory roles in the GSC
apoptotic pathway, differentiation, proliferation, migra-
tion and invasion, drug resistance, and radiation resis-
tance
[53-56]
. Like CSCs from other types of cancer, GSCs
are controlled by specific receptor signaling and the reg-
ulation of stem cell genes by transcription factors and
miRNAs. A number of new targets for these regulators
have been identified for GBM treatment and demon-
strated that miRNA expression patterns are correlated
with the developmental lineage and differentiation state
of tumor cells, as well as innovative biomarkers
[53-61]
.
Several published articles have summarized a wide range
of miRNAs in GSCs and the molecular mechanisms of
miRNAs involved in the signaling pathways regulating
these processes, as well as potential usefulness of
miRNAs for eliminating GSCs. From the viewpoint of
the CSC hypothesis, several deregulated miRNAs have
been strongly implicated in regulating the GSCs self-
renewal capacity, maintenance of stemness and plasticity,
and resistance to drugs and radiation therapy, as well as
unresponsiveness to apoptotic stimuli
[57,62-64]
. Therefore,
miRNAs can serve as potential targets for anti-GSC ther-
apeutics
[65-69]
. Using in silico analysis of the Cancer
Genome Atlas (TCGA), Wong et al.
[55]
recently identified
miRNAs associated with GBM and GSC survival, and
predicted GSC functions in GBM growth and progres-
sion. These authors used orthotopic xenograft GBM
mouse models and showed that inhibition of miR-148a
and miR-31 reduced proliferation, depleted GSCs, nor-
malized tumor vasculature, suppressed tumor growth,
and prolonged animal survival. These miRNAs inhibited
hypoxia-inducible factor 1 (FIH1), and the downstream
pathways involving hypoxia-inducible factor HIF1a as
well as Notch signaling. Therefore, miR-31 and miR-
148a regulate GBM growth by maintaining GSC growth
in their niche.
Down-regulation of miRNA-128 may contribute to
GBM, in part, by coordinately up-regulating ARP5
(ANGPTL6), Bmi-1 and E2F-3a, resulting in the pro-
liferation of undifferentiated GBM cells
[72]
. A link
between miR-128, which is significantly downregu-
lated in GBM, and the loss of GSC self-renewal which
occurs by direct regulation of the neural stem cell
(NSC) self-renewal factor B lymphoma Mo-MLV
insertion region 1 homolog (BMI1) has been shown
[73]
.
The Polycomb Repressor Complex (PRC) is an epige-
netic regulator of transcription and its action is
mediated by two protein complexes, PRC1 and
PRC2. PRC functions as an oncogene in GBM where
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it is involved in GSC maintenance and radioresistance.
miR-128 directly targets the mRNA of SUZ12, an
important component of PRC2, in addition to BMI1,
a component of PRC1
[74]
. This reduction of SUZ12
expression blocks the partially redundant functions of
PRC1/PRC2, thereby significantly reducing PRC activ-
ity and its associated histone modifications.
Epigenetic modifications regulate intratumoral het-
erogeneity, which is usually regulated by specific
GSC niches
[76]
. Moreover, GSC survival, proliferation,
and maintenance is regulated by oncogenic cytoprotec-
tive signaling pathways and epigenetic modifications
(Fig. 3)
[76]
. Recently, Nabilsi et al. investigated the
extent to which epigenetic differences contribute to
intratumoral cellular heterogeneity by developing
a high-throughput method, termed MAPit-patch
[76]
.
The authors found several differentially expressed
and methylated promoters that are associated with
altered gene expression between neural stem cell
(NSC) and GBM cell populations. In addition, con-
sidering each promoter individually, substantial epige-
netic heterogeneity was observed across the sequenced
molecules, indicating the presence of epigenetically
distinct cellular subpopulations within a GBM
tumor
[76]
. Their results showed the biological relevance
of epigenetically distinct subpopulations to the pheno-
typic heterogeneity of tumor cell populations.
Transcriptional mechanisms that control the pheno-
typic conversion of differentiated tumor cells into
tumor-propagating stem-like cells remain to be found.
Lopez-Bertoni recently showed that the reprogram-
ming transcription factors Oct4 and Sox2 trigger
GBM cells to change into stem-like and tumor-
propagating cells via a mechanism involving direct
DNA methyltransferase (DNMT) promoter transacti-
vation, leading to global DNA methylation and
DNMT-dependent downregulation of multiple
miRNAs
[77]
. They showed that one of the miRNAs,
miRNA-148a, inhibited GBM cell stem- l ike
properties and tumor-propagating potential. These
findings identify methylation- and microRNA-based
strategies for inhibiting the GSCs, their functions,
and contributions to tumor growth and recurrence
[77]
.
Particularly, a significant discovery was recently
reported by Kouri et al.
[56]
who identified miR-182
as a regulator of apoptosis, growth, and differentiation
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Fig. 3 Multiple signaling pathways in GSCs. A complex signaling pathway governs self-renewal, stemness, and maintenance of CSGs. Proteins in
these pivotal cellular pathways including several plasma membrane receptors, cytoplasmic signaling proteins, specific transcription factors, growth
factors, and ligands have the potential to be targeted for eradicating GSCs.
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programs whose expression level is correlated with
GBM patient survival
[76]
. The antitumor activity of
miR-182 resulted from its repression of Bcl2-like12
(Bcl2L12), c-Met, and hypoxia-inducible factor 2a
(HIF2a), as it results in enhanced therapeutic suscept-
ibility, decreased GSC spheroid size, expansion, and
stemness in vitro. Intravenously administered 182-
SNAs penetrated the blood-brain/blood-tumor barriers
(BBB/BTB) in orthotopic GBM xenografts of GBM
and selectively disseminated throughout the extravascu-
lar glioma parenchyma, triggering reduced tumor
burden and increased animal survival. These results
represent a novel and powerful strategy for GBM
therapy.
Identification of repurposed drugs for
GBM therapy
To discover novel and effective candidate therapeu-
tic drugs for anti-GBM and anti-GSCs, Cheng et al.
[78]
collected 356 GBM gene signatures from public data-
bases and use the Connectivity Map to systematically
evaluate the in vitro antitumor effects of 79 drugs in
GBM cell lines and GSCs. Using this strategy, these
authors selected the antipsychotic drug thioridazine
for further characterization due to its potent anti-
GBM and anti-GSC properties. Thioridazine induced
autophagy in GBM cells and in vivo as well as sup-
pressed GBM tumorigenesis. This work is particularly
important because it provided a new strategy to search
for drugs with anticancer and anticancer stem cell prop-
erties by using the Connectivity Map and repurposing
the antipsychotic drug thioridazine as an effective anti-
GBM and anti-GSC agent.
To identify new potent drugs for GBM therapy, Zhou et
al.
[79]
have combined two significant advances in GBM
research, (a) brain-penetrating polymeric nanoparticles
that can be loaded with drugs and are optimized for intra-
cranial convection-enhanced delivery, and (b) repurposed
compounds, previously approved drugs by Food andDrug
Administration (FDA), which were identified through
library screening to target GSCs. Using fluorescence ima-
ging and positron emission tomography, these authors
demonstrated that brain-penetrating nanoparticles can be
delivered intracranially in both rats and pigs. Using this
strategy, they identified several FDA approved agents that
when loaded into brain-penetrating nanoparticles and
administered by convection-enhanced delivery, one of
these compounds, dithiazanine iodide, significantly
increased survival in rats bearing GSC-derived xenografts.
To conceptually improve prognosis in recurrent GBM,
a treatment protocol based on a combination of drugs that
have not been used as cytotoxic chemotherapy agents but
that have been shown to be well tolerated and already
marketed and used for other non-cancer diseases was
recently developed by Kast et al.
[80]
. These authors found
nine drugs and added them to continuous low dose TMZ
in patients with recurrent disease after primary treatment
with concomitant administration of TMZ with radiother-
apy (Stupp Protocol). These drugs were aprepitant, artesu-
nate, auranofin, captopril, copper gluconate, disulfiram,
ketoconazole, nelfinavir, and sertraline, and were added
to continuous low dose TMZ. The authors discussed each
drug and the specific rationale for its use, and how each
drug is expected to retard GBM growth and undermine
GBM's compensatory mechanisms during TMZ treat-
ment. As discussed in this work, these drug combinations
may increase both quality of life and overall survival.
Epigenetic therapy to eradicate GSCs
Two signatures of malignancies including GBM are
aberrant gene function andalteredpatterns of gene expres-
sion, and evidence shows that epigenetic changes in
collaboration with genetic alterations cause dysregula-
tion in cancer
[81-82]
. The identification and development
of drugs to correct aberrant epigenetic changes in CSCs
requires knowledge of the extent and roles of epige-
netic reprogramming in these cells. The epigenetic
changes in cancer are potentially reversible, and treat-
ing CSCs with demethylating agents or HDAC inhibi-
tors may potentially reactivate silenced tumor
suppressor and TF genes
[82]
. DNA methyltransferase
(DNMT) 5-azacytidine (Aza) is an effective anticancer
agent and inhibitor of GSCs
[83-85]
. The current knowl-
edge of mechanisms underlying the inhibition of
DNA methylation by Aza and 5-Aza-2'-deoxycytidine
(Aza-dC), and of their apoptotic- and differentiation-
inducing effects on cancer stem and progenitor cells
in various cancers was recently reported
[86]
. Another
class of epigenetic inhibitors is HDAC inhibitors.
HDACs are a family of proteins that remove acetyl
groups from lysine residues of histone proteins and
other proteins including TFs
[87]
. These enzymes regulate
the conformation and activity of chromatin and mostly
function as transcriptional co-repressors as part of large
multi-protein complexes
[88]
. Combination of HDAC
inhibitors and DNA damaging agents synergi-
stically inhibit growth and induce apoptosis in GSC
cells possibly because they promote an open chromatin
conformation and allow more effective access of DNA
damaging agents to the chromatin, resulting in the
increased effectiveness of these agents
[17]
. Recent results
have demonstrated that specific combinations of his-
tone methyltransferase and deacetylase inhibitors signif-
icantly attenuated GSCs viability but had only a small
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effect on the growth of human bone marrow mesench-
ymal stem cells (hMSCs)
[88]
.
Conclusions and future directions
While several GSC targeted therapies have been iden-
tified, the usefulness of these compounds depends on
their pharmacokinetic and toxicity profiles, whether
they cross the blood-brain barrier (BBB), and whether
they have in vivo activity. A good source of useful
agents is repurposing FDA-approved drugs which are
clinically used for other diseases and may be effective
as single agents or they may have a synergistic effect
in combination with TMZ for eliminating the entire bulk
of GBM tumors. Among these, drugs that affect epige-
netic alterations, including HDAC inhibitors and DNA
methyltransferase (DNMT), approved for hematologi-
cal malignancies, are available for solid tumor ther-
apy
[89]
. Testing against GBM cells and GSCs, several
FDA-approved compounds that may be useful in
GBM treatment have been identified
[90]
and led to the
rational combination use of statins and topoisomerase
inhibitors for GBM therapy
[90]
. Furthermore, Hothi
et al. have identified disulfiram (DSF), an FDA
approved agent for the treatment of alcoholism, as cap-
able of inhibiting the growth of humanGSCs
[91]
. The sig-
nificance of this finding is that DSF is a relatively
nontoxic drug that can cross the BBB, and it is a direct
and potent inhibitor of human MGMT in brain tumor
cells
[91-92]
. Furthermore, the HDAC inhibitors trichosta-
tin A (TSA) and valproic acid (VPA) are FDA approved
drugs that significantly reduced proliferation rates,
decreased the expression of cancer stem cell markers,
and induced differentiation of these cells
[93]
. These
agents may increase the efficacy of conventional cancer
treatments for eliminating GSCs. Recent results demon-
strated that HDAC inhibitors in combination with erlo-
tinib may be a useful treatment option for newly
diagnosed tumors regardless of their EGFR status, as
well as for treatment-refractory, EGFR-overexpressing
GBM
[94]
. Moreover, the redox agent perylene-quinone
hypericin (HYP), a compound targeting multiple epige-
netic mechanisms
[95]
, has shown to be effective and
GBM patients have displayed stable disease and partial
responses to this agent.
While signif icant information on GSCs has
been published, identifying the specific and reliable
biomarkers of GSCs is critical for targeting these cells.
It is now documented that there are distinct subpopula-
tions of GSCs within a single GBM tumor. Therefore,
there is an urgent need to develop agents targeting differ-
ent signaling pathways and/or employing effective
multi-targeting agents to eliminate these distinct GSC
subpopulations which display several phenotypic, geno-
typic and epigenetic characteristics. Several lines of evi-
dence support a model of tumorigenicity with plasticity
between the non-GSC andGSC subpopulations within a
GBM tumor as well as interconversion of the differen-
tiated non-GSCs to GSCs upon chemotherapy treat-
ment
[15 ]
. Niche factors that play roles in the
interconversion between GSCs and non-GSCs may
provide specific niche-related targets to prevent
GSC plasticity and dedifferentiation. Moreover,
understanding the regulation of interconversion of
non-GSCs to GSCs should be high priority research
which may potentially lead to the development of
rational therapeutic approaches for GBM.
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